Abbott Laboratories to Acquire Exact Sciences for $21B

Abbott Laboratories ( (ABT) ) has provided an announcement.

On November 19, 2025, Abbott Laboratories announced a definitive agreement to acquire Exact Sciences Corporation, a leader in cancer screening and precision oncology diagnostics, for approximately $21 billion. This acquisition will allow Abbott to enter the fast-growing cancer diagnostics market, enhancing its growth profile and positioning it to transform cancer care through earlier detection and optimized treatment. The merger is expected to be immediately accretive to Abbott’s revenue growth and gross margin, with Exact Sciences becoming a wholly owned subsidiary. The transaction is anticipated to close in the second quarter of 2026, pending regulatory approvals and shareholder consent.

The most recent analyst rating on (ABT) stock is a Buy with a $162.00 price target. To see the full list of analyst forecasts on Abbott Laboratories stock, see the ABT Stock Forecast page.

Spark’s Take on ABT Stock

According to Spark, TipRanks’ AI Analyst, ABT is a Outperform.

Abbott Laboratories scores a 77, driven by strong financial performance and positive earnings call highlights. The company’s robust growth in medical devices and international markets, coupled with strategic product launches, supports its growth trajectory. Technical analysis indicates potential short-term weakness, but valuation remains reasonable, providing a balanced investment opportunity.

To see Spark’s full report on ABT stock, click here.

More about Abbott Laboratories

Abbott Laboratories is a global healthcare leader with a portfolio that includes diagnostics, medical devices, nutritionals, and branded generic medicines. The company operates in more than 160 countries and focuses on life-changing technologies across the healthcare spectrum.

Average Trading Volume: 5,816,638

Technical Sentiment Signal: Buy

Current Market Cap: $219.4B

For a thorough assessment of ABT stock, go to TipRanks’ Stock Analysis page.